Evidence map›Paper›PMID 22088620›Full record

ArticleAnnals of the rheumatic diseases2012

IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.

Timothy B Niewold, Jennifer A Kelly, Silvia N Kariuki, Beverly S Franek, Akaash A Kumar, Kenneth M Kaufman, Kenaz Thomas, Daniel Walker, Stan Kamp, Jacqueline M Frost and 18 more

Open access · greenAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 3 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. An Update on the Pathogenesis of Skin Damage in Lupus.Current rheumatology reports · 2020
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.Expert review of precision medicine and drug development · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Review
  19. Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19.Translational research : the journal of laboratory and clinical medicine · 2022
    Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 14 institutions in 4 countries.

Timothy B NiewoldSection of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois 60637, USA. tniewold@medicine.bsd.uchicago.edu
Jennifer A Kelly
Silvia N Kariuki
Beverly S Franek
Akaash A Kumar
Kenneth M Kaufman
Kenaz Thomas
Daniel Walker
Stan Kamp
Jacqueline M Frost
Andrew K Wong
Joan T Merrill
Marta E Alarcón-Riquelme
Mohammed Tikly
Rosalind Ramsey-Goldman
John D Reveille
Michelle A Petri
Jeffrey C Edberg
Robert P Kimberly
Graciela S Alarcón
Diane L Kamen
Gary S Gilkeson
Timothy J Vyse
Judith A James
Patrick M Gaffney
Kathy L Moser
Mary K Crow
John B Harley
Oklahoma Medical Research Foundation · USUniversity of Chicago · USUniversity of Alabama at Birmingham · USMedical University of South Carolina · USUniversity of Oklahoma · USUniversity of the Witwatersrand · ZACincinnati Children's Hospital Medical Center · USHospital for Special Surgery · USJohns Hopkins University · USKing's College London · GBMRC Unit for Lifelong Health and Ageing · GBNorthwestern University · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESThe University of Texas Health Science Center at Houston · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
ZINC AND CA EDTA THERAPY OF PLUMBISMM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · PI BELCHER, HAROLYN MILLICENT EDITH · 1985 to 2007
$37.3M
ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI LIU, CAMBRIAN YANGSHAO · 1990 to 2025
$29.8M
TRANSLATIONAL RESEARCH UNIVERSITY OF CHICAGO: CLINICAL TRIALSUL1RR024999 · NCRR · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2007 to 2011
$25.3M
MULTIDISCIPLINARY CLINICAL AND TRANSLATIONAL SCIENCE (MCTS) PROGRAM (UL1)UL1RR025741 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GREENLAND, PHILIP · 2008 to 2011
$24.7M
THE EFFECTS OF ERK PATHWAY INHIBITION ON DNA METHYLATION IN SLEP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CENTOLA, MICHAEL B · 2000 to 2009
$21.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) INTENSIVE PHARMACOKINETICS STUDYM01RR000048 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DUNAIF, ANDREA · 1985 to 2007
$21.1M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2004 to 2011
$21.0M
ZINC AND COPPER METABOLISM IN COLLAGEN DISORDERSM01RR001070 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI REVES, JOSEPH G · 1985 to 2009
$16.3M
The Slamf3, Slamf5, and Slamf6 receptor-induced pathways to murine lupusP01AI065687 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TERHORST, CORNELIS P · 2006 to 2016
$14.7M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
NCATS NIH HHS UL1 TR000062NCI NIH HHS CA141700NCI NIH HHS R01 CA141700NCRR NIH HHS M01 RR000048NCRR NIH HHS M01 RR000052NCRR NIH HHS M01 RR001070NCRR NIH HHS MO1-RR00052NCRR NIH HHS MO1-RR0048NCRR NIH HHS P20 RR015577NCRR NIH HHS P20 RR020143NCRR NIH HHS P30 RR031152NCRR NIH HHS RR-01070NCRR NIH HHS RR024999NCRR NIH HHS RR025741NCRR NIH HHS RR15577NCRR NIH HHS RR20143NCRR NIH HHS UL1 RR024999NCRR NIH HHS UL1 RR025741NCRR NIH HHS UL1 RR029882NCRR NIH HHS UL1RR029882NIAID NIH HHS AI059893NIAID NIH HHS AI063274NIAID NIH HHS AI065687NIAID NIH HHS AI071651NIAID NIH HHS AI083790NIAID NIH HHS AI24717NIAID NIH HHS AI31584NIAID NIH HHS AI53747NIAID NIH HHS AI62629NIAID NIH HHS K08 AI083790NIAID NIH HHS L30 AI071651NIAID NIH HHS P01 AI065687NIAID NIH HHS R01 AI024717NIAID NIH HHS R01 AI031584NIAID NIH HHS R01 AI059893NIAID NIH HHS R01 AI063274NIAID NIH HHS R21 AI053747NIAID NIH HHS R37 AI024717NIAID NIH HHS R56 AI063274NIAID NIH HHS U19 AI062629NIAMS NIH HHS AR002138NIAMS NIH HHS AR045084NIAMS NIH HHS AR049459NIAMS NIH HHS AR052125NIAMS NIH HHS AR053483NIAMS NIH HHS AR058621NIAMS NIH HHS AR060861NIAMS NIH HHS AR33062,NIAMS NIH HHS AR42460NIAMS NIH HHS AR42476NIAMS NIH HHS AR48940NIAMS NIH HHS AR49084NIAMS NIH HHS K24 AR002138NIAMS NIH HHS N01 AR062277NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR048940NIAMS NIH HHS P60 AR030692NIAMS NIH HHS P60 AR049459NIAMS NIH HHS P60 AR062755NIAMS NIH HHS R01 AR033062NIAMS NIH HHS R01 AR042460NIAMS NIH HHS R01 AR042476NIAMS NIH HHS R01 AR052125NIAMS NIH HHS R01 AR060861NIAMS NIH HHS RC1 AR058621NIDCR NIH HHS DE15223NIDCR NIH HHS R01 DE015223NIDDK NIH HHS DK42086NIDDK NIH HHS P30 DK042086NIGMS NIH HHS P30 GM103510Wellcome Trust
6 · The paper itself

Abstract

objectiveHigh serum interferon α (IFNα) activity is a heritable risk factor for systemic lupus erythematosus (SLE). Auto-antibodies found in SLE form immune complexes which can stimulate IFNα production by activating endosomal Toll-like receptors and interferon regulatory factors (IRFs), including IRF5. Genetic variation in IRF5 is associated with SLE susceptibility; however, it is unclear how IRF5 functional genetic elements contribute to human disease.

methods1034 patients with SLE and 989 controls of European ancestry, 555 patients with SLE and 679 controls of African-American ancestry, and 73 patients with SLE of South African ancestry were genotyped at IRF5 polymorphisms, which define major haplotypes. Serum IFNα activity was measured using a functional assay.

resultsIn European ancestry subjects, anti-double-stranded DNA (dsDNA) and anti-Ro antibodies were each associated with different haplotypes characterised by a different combination of functional genetic elements (OR>2.56, p<1.9×10(-14) for both). These IRF5 haplotype-auto-antibody associations strongly predicted higher serum IFNα in patients with SLE and explained >70% of the genetic risk of SLE due to IRF5. In African-American patients with SLE a similar relationship between serology and IFNα was observed, although the previously described European ancestry-risk haplotype was present at admixture proportions in African-American subjects and absent in African patients with SLE.

conclusionsThe authors define a novel risk haplotype of IRF5 that is associated with anti-dsDNA antibodies and show that risk of SLE due to IRF5 genotype is largely dependent upon particular auto-antibodies. This suggests that auto-antibodies are directly pathogenic in human SLE, resulting in increased IFNα in cooperation with particular combinations of IRF5 functional genetic elements. SLE is a systemic autoimmune disorder affecting multiple organ systems including the skin, musculoskeletal, renal and haematopoietic systems. Humoral autoimmunity is a hallmark of SLE, and patients frequently have circulating auto-antibodies directed against dsDNA, as well as RNA binding proteins (RBP). Anti-RBP autoantibodies include antibodies which recognize Ro, La, Smith (anti-Sm), and ribonucleoprotein (anti-nRNP), collectively referred to as anti-retinol-binding protein). Anti-retinol-binding protein and anti-dsDNA auto-antibodies are rare in the healthy population. These auto-antibodies can be present in sera for years preceding the onset of clinical SLE illness and are likely pathogenic in SLE.

Indexed as

Antibodies, AntinuclearAutoantibodiesBlack or African AmericanCase-Control StudiesDNAGenetic Predisposition to DiseaseGenotypeHaplotypesHumansInterferon-alphaInterferon Regulatory FactorsLupus Erythematosus, SystemicPolymorphism, Single NucleotideWhite PeopleAntibodies, AntinuclearAutoantibodiesDNAInterferon-alphaInterferon Regulatory FactorsIRF5 protein, humanSS-A antibodies

Identifiers

PMID22088620
PMCPMC3307526
OpenAlexW2117433422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.